Health

  • August 06, 2026

    Goodwin, Covington Lead Braveheart Bio's $383M IPO

    Venture-backed biotechnology firm Braveheart Bio hit the public markets on Thursday after raising $383 million in its upsized initial public offering.

  • August 06, 2026

    Tarsus Bets Up To $800M On Alkeus In Retina Therapy Push

    Tarsus Pharmaceuticals Inc. said Thursday it has agreed to acquire privately held Alkeus Pharmaceuticals Inc. for up to approximately $800 million, expanding the Irvine, California-based eye care company's pipeline into retinal disease with an experimental treatment for Stargardt disease.

  • August 06, 2026

    Shein Eyes $40B Valuation Via Hong Kong IPO, More Rumors

    Fast-fashion company Shein is seeking a $40 billion valuation through its Hong Kong initial public offering, betting platform Polymarket is eyeing a new funding round that could value it at $20 billion and Cencora's MWI Animal Health merger with Covetrus faces regulatory scrutiny.

  • August 06, 2026

    Eli Lilly, Novo Nordisk Antitrust Suit Tossed By Texas Judge

    A Texas federal court has dismissed compounding pharmacy Strive Specialties Inc.'s antitrust lawsuit against Eli Lilly and Novo Nordisk, finding it failed to allege the companies blocked competition for GLP-1 medications.

  • August 06, 2026

    Judge OKs $35M Teva Deal In Delayed Generic Inhalers Suit

    A Massachusetts federal judge has approved an antitrust settlement that will see Teva Pharmaceuticals pay $35 million to resolve claims that it schemed to delay generic competition for its QVAR asthma inhalers.

  • August 05, 2026

    Product Liability Cases To Watch: Midyear Report

    Social media companies are headed back to court over allegations that their platforms are designed to hook young people, while OpenAI faces claims that ChatGPT has meted out harmful health advice and helped users plan mass shootings. Here's what's on the radar for product liability for the rest of 2026.

  • August 05, 2026

    Drug Cos. Can't Trim Humana's Price-Fix Claims In Bellwether

    A Pennsylvania federal judge on Tuesday denied a bid by a number of generic drug manufacturers to dismiss two antitrust claims brought by health insurer Humana Inc. from an upcoming bellwether trial in long-running antitrust multidistrict litigation, finding they were brought within the statute of limitations.

  • August 05, 2026

    Kansas Judge Permanently Blocks Abortion Care Restrictions

    A Kansas state court has permanently enjoined a slew of restrictions on abortion care, including requirements that providers disclose patients' reasons for seeking an abortion to the state and inform patients about abortion pill "reversal" treatments the court said were "unlikely to be biologically plausible."

  • August 05, 2026

    Takeda Says Rebates, Subsidies Cut $885M IBS Drug Verdict

    Takeda Pharmaceuticals battled with a class of health plans over whether a Massachusetts federal jury's $885 million antitrust verdict against the drugmaker for conspiring to delay generic competition to anticonstipation drug Amitiza should be reduced by rebates the drugmaker paid and Medicare subsidies that reduced the health plans' costs.

  • August 05, 2026

    HHS Decertifies Ky. Organ Group Amid Investigation

    After a federal investigation found that a Kentucky organ procurement organization moved forward to recover the organs of a man showing signs of life, the Department of Health and Human Services has announced it's revoking the group's certification. 

  • August 05, 2026

    Aetna, Others Hit Pharma Cos. With Xifaxan Pay-To-Delay Suit

    Health insurance companies Aetna Inc., Health Care Service Corp. and Molina Inc. have sued multiple pharmaceutical companies in Pennsylvania state court in Pittsburgh, alleging that the defendants conspired to delay the release of generic versions of the irritable bowel syndrome drug Xifaxan, in violation of antitrust laws.

  • August 05, 2026

    Mich. Parents Seek $375K In Newborn Blood Spot Case

    A group of Michigan parents has asked a federal judge to award nearly $375,000 in attorney fees and costs after they secured a consent judgment that ended part of the state's newborn blood spot retention program and required the destruction of about 3.4 million samples. 

  • August 05, 2026

    No Coverage For Assisted Living Death, Fla. Panel Says

    A Florida appellate court on Wednesday reversed a judgment that required National Assisted Living Risk Retention Group to provide coverage for a wrongful death suit from a resident's 2012 death, finding no claim was made during the relevant policy period.

  • August 05, 2026

    Fenwick-Led Attovia Therapeutics Prices Upsized $289M IPO

    Early-stage biotechnology company Attovia Therapeutics hit the public markets on Wednesday after it raised $289 million in its upsized initial public offering.

  • August 05, 2026

    Texas Firm Lands $150M HHS Services Deal For Migrant Kids

    The U.S. Department of Health and Human Services said it has entered into a $150 million contract with a small Texas law firm to provide legal services to unaccompanied immigrant children, raising concerns from former subcontractors about the firm's experience with immigration matters.

  • August 05, 2026

    Pa. Court Wipes Out $19M Verdict In Nursing Home Death Suit

    A Pennsylvania appeals court has vacated $19 million in damages, including $15 million in punitive damages, in a suit against nursing home operators and managers over the death of a resident, finding the trial court should have reconsidered damages after negating liability against two of the four defendants.

  • August 05, 2026

    Glenmark Pharma Hit With Safety Suit After Carvedilol Recalls

    Glenmark Pharmaceuticals' generic drug carvedilol, used to treat high blood pressure and congestive heart failure, was misrepresented as therapeutically equivalent to the brand-name drug Coreg but contained undisclosed nitrosamine impurities that changed its strength, quality and safety profile, according to a proposed class action filed Tuesday in Washington federal court.

  • August 05, 2026

    Revive Rx Can't End Eli Lilly's Suit Over Tirzepatide Drugs

    A Texas federal judge has denied Revive Rx's bid to end Eli Lilly and Co.'s remaining unfair competition claims over the compounding pharmacy's sales of allegedly unapproved tirzepatide weight loss drugs that Eli Lilly says compete with Mounjaro and Zepbound, rejecting Revive's argument that compounded drugs fall outside state "new drug" laws.

  • August 05, 2026

    King & Spalding Hires Crowell Healthcare Consulting Leader

    King & Spalding LLP has announced the hiring of a Crowell & Moring LLP partner who was also the managing director of Crowell Health Solutions, a consulting vertical that his former firm launched four years earlier.

  • August 04, 2026

    TikTok Settles 3 Teen Addiction Suits Before Bellwether Trials

    The company behind TikTok settled three lawsuits brought by young people alleging the social media platform caused them mental health harm, a lawyer for the plaintiffs said Tuesday, although three other social media companies are still scheduled to go to trial in Los Angeles on the claims in October.

  • August 04, 2026

    Colo. Panel Mulls Med Mal Retrial Bid Over Pretrial Meeting

    A Colorado man urged a state appellate court Tuesday to order a new trial in his medical malpractice lawsuit in which jurors sided with his physicians, arguing to a skeptical panel that the defense's ex parte pretrial meeting with his own treating surgeon caused him prejudicial harm.

  • August 04, 2026

    3rd Circ. Won't Give Ex-Olympus Exec Another Go At FCA Suit

    The Third Circuit has declined to revive a whistleblower suit by Olympus Corp.'s former employee who claimed he was fired after reporting FDA regulatory violations, ruling Tuesday that he failed to state a retaliation claim under the False Claims Act since he didn't link his concerns to a reasonable belief that Olympus defrauded the government.

  • August 04, 2026

    Health Provider To Pay $14.1M To Settle False Diagnoses Suit

    A healthcare provider with headquarters in Florida has agreed to pay the federal government $14.1 million to resolve allegations it entered false diagnosis codes to increase the payments it received from the Medicare Advantage program.

  • August 04, 2026

    Healthcare Fraud Task Force Expands To Philly, Charges 19

    Federal and Pennsylvania law enforcement officials on Tuesday announced charges against 19 defendants involved in home care, alleging they bilked Medicare and Medicaid out of funds meant for caregivers and beneficiaries — representing an expansion of the federal crackdown on benefits fraud to Philadelphia.

  • August 04, 2026

    Kirkland, Jones Day Guide P&G's $3.8B Buy Of Thorne

    Procter & Gamble is acquiring supplements company Thorne from L Catterton for $3.8 billion in cash, with Kirkland & Ellis LLP and Jones Day serving as legal advisers in the transaction, the companies announced Tuesday.

Expert Analysis

  • How To Brace For A Potential Democratic Oversight Push

    Author Photo

    With the possibility of a shift in congressional control after the November midterm elections, companies and their general counsel should prepare now by mapping oversight exposure, reviewing government interactions, preserving records and developing coordinated communications strategies, say attorneys at Hogan Lovells.

  • Remote Work Rulings Show ADA Fights Hinge On Process

    Author Photo

    Two opposite outcomes in recent Fifth Circuit and D.C. federal court cases underscore that the legality of denying employees' disability accommodation requests for remote work depends less on broad policy and more on how it's applied, says Paul Sweeney at Ice Miller.

  • Series

    Being A Magician Makes Me A Better Lawyer

    Author Photo

    The skills I've developed as a lifelong magician have translated directly into tangible benefits in the courtroom because performing magic and trying cases both live at the intersection of psychology, storytelling, timing and disciplined rehearsal, says Mark Dombroff at Fox Rothschild.

  • How Litigants Are Testing Conversion Therapy Ruling's Scope

    Author Photo

    Litigants are already using the U.S. Supreme Court’s recent Chiles v. Salazar ruling, which applied strict scrutiny to Colorado’s conversion therapy ban, to challenge laws limiting algorithmic rental pricing, artificial intelligence-based discrimination and anti-union employer speech, and courts must soon decide Chiles’ First Amendment limits, say attorneys at O'Melveny.

  • Illinois Audit Law Will Make AI Clauses Actually Enforceable

    Author Photo

    A law recently enacted in Illinois creates a first-in-the-nation requirement for artificial intelligence developers to undergo annual audits, providing objective standards that can be incorporated into private contracts and addressing the problem of defining responsible AI use, says William Tanenbaum at Moses & Singer.

  • How Justices' TPS Ruling Affects Workforce Planning

    Author Photo

    The U.S. Supreme Court’s recent holding in Mullin v. Doe that courts lack jurisdiction to review temporary protected status determinations greenlights the end of TPS for thousands of Syrian and Haitian nationals, and means employers must reevaluate TPS-designees' employability while avoiding discriminatory document practices, says attorney Richard Herman.

  • A New Regulatory Environment For PE In Calif. Healthcare

    Author Photo

    The California Office of Health Care Affordability's proposed revisions to its cost and market impact review regulations, amid broader state scrutiny of private equity-backed healthcare arrangements, represent a qualitative shift in California's regulatory posture toward institutional healthcare investment, say attorneys at Ropes & Gray.

  • Justices' Ruling Alters Playing Field For State Subpoena Suits

    Author Photo

    The U.S. Supreme Court’s decision in First Choice Women’s Resource Centers v. Davenport will spark more federal court challenges to state subpoenas, but procedural defenses will block some merits decisions, so plaintiffs must carefully time and manage parallel federal and state proceedings, say attorneys at Troutman.

  • FDA Moves Leave Peptides In A Legal Gray Zone

    Author Photo

    While the U.S. Food and Drug Administration has taken a concrete step forward on reclassifying certain peptides, the practical consequence of their interim status cannot be overstated — these substances are no longer designated as posing a significant safety risk, but they have not been affirmatively authorized for compounding, say attorneys at Sheppard.

  • Series

    Bass Fishing Makes Me A Better Lawyer

    Author Photo

    Landing a trophy striped bass and closing a big deal both require cultivating the patience to finesse — not force — your way to desired outcomes, changing course when your old approach isn’t working and learning from the ones that got away, says Jon Ruiss at Alston & Bird.

  • Series

    NY Banking Brief: All The Notable Legal Updates In Q2

    Author Photo

    The year's second quarter brought several notable banking law developments to New York, including a proposal to align state stablecoin rules with the federal Genius Act, fresh fair lending and cybersecurity guidance from state regulators, and a significant Second Circuit holding on preemption, say attorneys at Ashurst Perkins Coie.

  • Roundup

    The Most Talked-About Supreme Court Decisions Of 2026

    Author Photo

    This term, 11 U.S. Supreme Court decisions quickly became hot topics among Law360's guest writers.

  • A New Defense For Medicaid Fraud Cases In Texas

    Author Photo

    The Texas Supreme Court decision in LabCorp v. Texas last month, finding that the state's False Claims Act requires proof that an omission is material, is among the first to establish that the government's lack of reaction to the defendant's disclosures rendered alleged omissions immaterial, say attorneys at Sheppard.

  • Pregnancy Bias Suits Highlight EEOC's Expanding Reach

    Author Photo

    Recent U.S. Equal Employment Opportunity Commission suits show that enactment of the Pregnant Workers Fairness Act has drawn scrutiny to a wider range of employment decisions and an increasing focus on individual decisions as indicators of whether an employer's policies comply with evolving federal requirements, say attorneys at Krevolin Horst.

  • Quantum Readiness May Paradoxically Raise Contractor Risk

    Author Photo

    The organizations best positioned for the cryptographic system migration deadlines and other requirements under President Donald Trump’s recent quantum executive orders will be those able to inventory their cryptographic dependencies while protecting their vulnerability road map from adversaries, says Jesse Lemon at The Beckage Firm.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.